Data from Global RACT Analysis Reveals Subjectivity

What are the most common risks in clinical trials?
What challenges faces TransCelerate RACT?

Read the answers in the latest article published on ACT.

by Moe Alsumidaie, Beat Widler, PhD, Peter Schiemann, PhD, Artem Andrianov, Ph D

Do you want to know about @RACT more and start using it?

Start using it now.

By Artem Andrianov, Ph.D., MBA|2020-09-23T09:43:22+02:00May 11, 2016|Blog|0 Comments

About the Author: Artem Andrianov, Ph.D., MBA

Professional in the integration of data-driven Risk-based Quality Management (RBQM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, Health 2.0, DGGF, etc. 18+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RBQM research to new frontiers for CROs, pharma and biotech companies.